An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Trial Profile

An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Capecitabine; Cisplatin; Trastuzumab
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms JOSHUA
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 30 May 2017 Planned End Date changed from 30 Jun 2017 to 30 Sep 2017.
    • 05 Apr 2017 Planned End Date changed from 1 May 2019 to 30 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top